|
|
|
|
Vol. 19, Issue 8, 3221-3233, August 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Molecular Medicine and Genetics, Department of Internal Medicine, The Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109
Submitted January 9, 2008;
Revised May 6, 2008;
Accepted May 12, 2008
Monitoring Editor: Mark H. Ginsberg
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Similar in its overall domain structure to the larger family of secreted MMPs, the MT1-MMP zymogen is composed of a propeptide domain, a Zn-containing catalytic domain, a flexible linker peptide, and a hemopexin-like domain near its carboxy terminus (Itoh and Seiki, 2006
). In contrast to the secreted MMPs, however, the MT1-MMP hemopexin domain is extended to include a glutamic acid-rich stem region that connects the extracellular face of the proteinase to a single-pass transmembrane segment that terminates in a short, 20-amino acid cytosolic tail (Itoh and Seiki, 2006
). In its membrane-tethered configuration, studies to date have largely focused on the ability of MT1-MMP to bind and process the secreted metalloproteinase zymogens, MMP-2 and MMP-13, to catalytically active forms (Sato et al., 2005
; Itoh and Seiki, 2006
). The MT1-MMP catalytic domain displays, however, an unusually broad substrate specificity that not only allows the proteinase to hydrolyze directly multiple ECM components but also to cleave integrins, adhesion molecules, surface proteoglycans, and receptors as well as trigger signal transduction cascades (Sato et al., 2005
; Itoh and Seiki, 2006
; Basile et al., 2007
; Nyalendo et al., 2007
). Moreover, in a manner that further distinguishes MT1-MMP from secreted MMP family members, the MT1-MMP cytosolic tail has been proposed to control protease endocytosis and recycling, distribution at the cell surface, and interaction with intracellular signaling molecules (Itoh and Seiki, 2006
; Nyalendo et al., 2007
; D'Alessio et al., 2008
).
As new insight into MT1-MMP structure and function has been brought to bear, increasingly complex schemes have been proposed to underlie the protease's impact on cell behavior (Itoh et al., 2006
; Itoh and Seiki, 2006
; Lafleur et al., 2006
; Nyalendo et al., 2007
; D'Alessio et al., 2008
). Nonetheless, the majority of these studies have been restricted to analyses of cell–matrix interactions that take place under two-dimensional (2-D) culture conditions that either fail to recapitulate three-dimensional (3-D) ECM environments or with matrix composites devoid of the physiological cross-links that characterize normal tissues (Chun et al., 2006
; Hotary et al., 2006
; Yamada and Cukierman, 2007
). Herein, we characterize MT1-MMP deletion mutants and chimeric constructs that serve to identify the key domains that underlie pericellular proteolysis, substrate specificity, and 3-D tissue-invasive activity in vitro and in vivo. Unexpectedly, by expressing active, membrane-tethered forms of a secreted collagenase on the surface of invasion-incompetent host cells, we find that collagen-invasive activity can be generated de novo independently of a specific requirement for the MT1-MMP catalytic, hemopexin, type I transmembrane, or cytosolic tail domains. By contrast, the structural rules underlying fibrin-invasive activity are more stringent in terms of requiring the participation of both MT-MMP–specific catalytic and hemopexin domains. These studies establish a new, and heretofore unpredicted, molecular basis for constructing the membrane-tethered, proteolytic machinery that arms mammalian cells with tissue-invasive activity in the 3-D setting.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Construction of Expression Plasmids
Full-length MT1-MMP, hemagglutinin (HA)-tagged MT1-MMP, MT3-MMP, MMP-2, MMP-13, soluble MT1-MMP (MT1
TM), cytosolic tail truncated mutant MT1-MMP (MT1
CT), and catalytically inactive MT1-MMP (E/A; Glu240
A) were described previously (Hotary et al., 2000
; Yana and Weiss, 2000
; Chun et al., 2004
). MT1
IS-2 (Pro163-Gly170 deleted) and MT1
polyE (Glu519-Glu532 deleted) were constructed using the overlap extension method. Using overlapping primers with polymerase chain reaction (PCR) combination methods described previously (Pei and Weiss, 1995
), MT1/MT3HPX was generated by combining fragments of MT1-MMP (Met1-Gly284) and MT3-MMP (Pro292-Val607). MT1/MMP-1CAT, MT1/MMP-1CAT
CT, and MT1/MMP-1CAT
TM were generated by combining HFC+10 (Met1-Tyr270) (Pei and Weiss, 1995
) with fragments of MT1-MMP (Gly284-Val582), MT1
CT (Gly284-Arg563), or MT1
TM (Gly284-Gly535), respectively. MT1-MT6 · GPI was constructed by combining fragments of MT1-MMP (Met1-Gly535) and MT6-MMP (Asp531-Arg562) (Kojima et al., 2000
). MT1-IL2R · CT was generated by combining MT1-MMP (Met1-Arg563) with the cytosolic tail of IL-2R
(Ser257-Ile272) (Nakahara et al., 1997
), whereas MT1-IL2R · TM was constructed by combining an MT1-MMP fusion construct between MT1-MMP (Met1-Arg535) and the transmembrane domain of IL2R (Nakahara et al., 1997
) with the MT1-MMP cytosolic tail (Arg563-Val582). MT1
PEX (deleted Cys318-Gly535) was obtained from D. Q. Pei (University of Minnesota). MT1/MMP-1CAT
PEX was generated from MT1/MMP-1CAT by deleting the PEX domain of MT1 (Cys318-Gly535); MT1
PEX
CT and MT1
PEX-MT6 · GPI were generated from MT1
CT and MT1-MT6 · GPI accordingly. All MT1-MMP mutants were subcloned into pCR3.1 vector for expression studies.
Collagen, Gelatin, and Fibrin Degradation Assays
Collagen gel films (
100 µg/cm2) or fibrin films (
150 µg/cm2) were labeled with Alexa Fluor-594 (Invitrogen, Carlsbad, CA) as described previously (Hotary et al., 2002
; Sabeh et al., 2004
). COS cells (5 x 104) were cultured atop the collagen films for 3 d in DMEM/10% FBS at either 37 or 25°C, and fluorescence images of labeled collagen were captured by laser confocal microscopy (Sabeh et al., 2004
). Collagen degradation products were quantified by hydroxyproline release (Sabeh et al., 2004
). Subjacent gelatin degradation was monitored as described previously (Yana and Weiss, 2000
).
Invasion Assays
Collagen and fibrin invasion assays were performed as described previously (Hotary et al., 2000
, 2002
). In brief, 1 x 105 COS cells, suspended in DMEM/10% FBS, were added to the upper well of 24-mm Transwell dishes (Corning, Corning, NY) that contained either a 3-D gel of wild-type or r/r type I collagen (1 ml final volume of 2.2 mg/ml; Hotary et al., 2003
) or cross-linked fibrin (1 ml final volume of 3.0 mg/ml). After a 3-d culture period, the number of invasive foci was counted in randomly selected high-powered fields (hpf) (Sabeh et al., 2004
).
Gelatin Zymography, Western Blotting, and Antibodies
Gelatin zymography and Western blot analysis (using rabbit polyclonal antisera against the MT1-MMP hemopexin or catalytic domains) were performed as described previously (Lehti et al., 2000
; Yana and Weiss, 2000
). For MT1-MMP trafficking and cell surface localization studies, anti-HA antibody (12CA5; Roche Diagnostics) was tagged with an Alexa Fluor-488 antibody labeling kit (Invitrogen) according to the manufacturer's protocol.
Chick Chorioallantoic Membrane (CAM) Invasion Assays
COS cell invasion in vivo was assessed using the 11-d-old chick embryo CAM as described previously (Sabeh et al., 2004
). COS cells (2 x 105/assay) were labeled with Fluoresbrite carboxylate microspheres (45 nm in diameter; Polysciences, Warrington, PA), and the percentage of invading cells (Inv) was quantified in three or more randomly selected fields (ImageQuant; GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom). Depth of invasion from the CAM surface (invasion front [IF]) was defined as the leading front of three or more invading cells in randomly selected fields (1 U = 200 µm).
Cell Surface Biotinylation, MT1-MMP Internalization, and Recycling
Cell surface MT1-MMP expression was determined after surface biotinylation and immunoprecipitation as described previously (Yana and Weiss, 2000
). For MT1-MMP internalization, cells were incubated for 1 h on ice in the presence of 0.5 mg/ml NHS-SS-biotin (Pierce Chemical, Rockford, IL) (Fabbri et al., 1999
). Labeled cells were then washed and incubated at 37°C for the times indicated to allow for internalization. Samples were then washed and treated successively (20 min at 4°C) with a reducing solution (42 mM glutathione, 75 mM NaCl, 1 mM EDTA, 1% bovine serum albumin, and 75 mM NaOH) to strip biotinylated proteins from the cell surface. After a final wash, cells were lysed in 10 mM Tris, pH 7.2, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, and 1% Nonidet P-40. Biotinylated proteins were captured with streptavidin-Sepharose beads (Pierce Chemical), and recovered complexes were resolved under reducing conditions by SDS-PAGE followed by Western blot analysis (Fabbri et al., 1999
). The total pool of biotinylated MT1-MMP was determined in samples where the incubation step with the reducing solution was omitted. For recycling studies, biotinylated surface proteins were internalized at 37°C, the cells washed in reducing buffer and the pool of internalized MT1-MMP allowed to recycle to the cell surface over a 60-min culture period at 37°C in duplicate samples. At the end of the recycling period, one of the two samples was reduced to quantify the amount of protein that remained intercellular, whereas the other sample was left unreduced to determine the total MT1-MMP pool size. The percentage of MT1-MMP internalized or externalized was estimated by densitometric analysis of immunoblots (Yana and Weiss, 2000
).
To visualize trafficking of either HA-tagged MT1-MMP or MT1
CT in transfected COS cells, cell surface proteases were labeled with Alexa Fluor-tagged anti-HA antibody in the presence of 25 µg/ml Texas (TX) Red-transferrin (Tf) (Invitrogen) for 1 h at 4°C. After a 40-min incubation at 37°C, cells were fixed and processed for confocal imaging.
Small Interfering RNA (siRNA) Electroporation and Reverse Transcription (RT)-PCR Analysis
The antisense strand of siRNA was targeted against a 21-nt MT1-MMP sequence (5'-AAC AGG CAA AGC TGA TGC AGA-3'; nt 228–248). The nucleotide sequence was scrambled to generate an siRNA control sequence (5'-AAG TGA TCA AGC ACC GAA GAG-3'). Human (h)MMP-1 was targeted using 21-nt sequences (5'-AAG ATG TGG ACT TAG TCC AGA-3'). siRNA oligonucleotides (QIAGEN, Valencia, CA) were introduced into tumor cells (50–100 nM) using a nucleofector kit and electroporation (Amaxa Biosystems, Gaithersburg, MD) as described previously (Sabeh et al., 2004
). Total RNA was isolated using TRIzol reagent (Invitrogen). RT-PCR was performed with 1 µg of total RNA and 10 µM of specific primers (Hotary et al., 2002
) by using One-Step RT-PCR System reagent (Invitrogen).
| RESULTS |
|---|
|
|
|---|
|
A point mutation in its catalytic domain; MT1-MMP(E/A)] can trigger 2-D motility and cell signaling (Cao et al., 2004
|
|
IS-2) displays a significant defect in its ability to activate MMP-2 (Figure 4A) (English et al., 2001
polyE-box mutant maintains MMP-2–processing activity (Figure 4A) and expresses full collagenolytic activity (Figure 4, B and C) as well as invasive activity (Inv) in vitro (Figure 4C) and in vivo (Inv, 14.2 ± 1.5 and IF, 21 ± 0.6; mean ± 1 SD, n = 3).
|
PEX), and the functional activity of the membrane-tethered, mutant enzyme was assessed. Unexpectedly, MT1
PEX-transfected COS cells continue to display significant collagenolytic activity (Figure 4, B and C). The ability of hemopexin-deleted MT1-MMP to degrade type I collagen cannot be ascribed to partial unwinding of the type I collagen triple helix at 37°C because collagenolytic activity is similarly detected at 25°C (Figure 4B) (Lee et al., 2006
PEX), degradative and invasive activities are maintained (Figure 4, C and D).
Regulation of MT1-MMP Proteolytic Activity at the Cell Surface
MT1-MMP is tethered to the cell surface by a single-pass transmembrane domain that terminates in a 20-amino acid cytosolic tail that has been reported to contain structural information critical to proteinase trafficking as well as proteinase localization to invadopodia at the cell surface (Nakahara et al., 1997
; Lehti et al., 2000
; Uekita et al., 2001
; Itoh and Seiki, 2006
; Nyalendo et al., 2007
). Consistent with recent studies that have identified endocytotic motifs in the MT1-MMP tail (Uekita et al., 2001
; Anilkumar et al., 2005
; Itoh and Seiki, 2006
), the surface-localized, HA-tagged wild-type protease (labeled with fluorescent anti-HA antibody at time 0 at 4°C) is internalized rapidly into a transferrin (TF)-positive recycling compartment during a 40-min chase at 37°C (Figure 5A). After surface biotinylation,
50% of MT1-MMP is internalized, with almost 80% of the protease recycled to the cell surface as described previously (Figure 5A) (Itoh and Seiki, 2006
). By contrast, tail-deleted MT1-MMP (MT1
CT) is internalized at markedly reduced rates (i.e.,
20% of the surface biotinylated enzyme is endocytosed), whereas exocytosis proceeds at rates comparable with those observed with the wild-type enzyme (i.e.,
50% recycled; Figure 5A). Despite the marked effects that deleting the cytosolic tail exerts on MT1-MMP internalization, COS cells transfected with HA-tagged MT1
CT and cultured on a substratum of heat-denatured collagen (i.e., gelatin), a matrix derivative that allows for the rapid visualization of proteolytic zones, concentrate degradative activity in MT1-MMP–positive foci indistinguishable from those generated by the HA-tagged wild-type enzyme (Figure 5B). Furthermore, both subjacent type I collagenolysis and the invasive activity of MT1-MMP are retained in vitro and in vivo regardless of whether the cytosolic tail is deleted (Figure 5, C and D) or replaced with that of the IL2 receptor (MT1-IL2R · CT) (Supplemental Figure 3). In similar manner, COS cells expressing the MT1/MMP-1CAT chimera or MT1
PEX constructs in which the respective cytosolic tails have been deleted also express collagenolytic and proinvasive activities (Supplemental Figure 3). Noteworthy, however, is the fact that the invasive activity of the internalization-defective MT1
CT mutant demonstrates a heightened sensitivity to inhibition by exogenous TIMP-2, presumably as a consequence of the inability of the tail-deleted construct to regenerate itself as an active proteinase (i.e., by dissociating the reversible inhibitor away from the MT1-MMP catalytic domain during recycling; Maquoi et al., 2000
; Zucker et al., 2004
) (Figure 5C).
|
PEX to the cell surface via the MT6-MMP GPI anchor (Figure 6 and Supplemental Figure 3). Despite the facts that 1) the cell surface levels of GPI-anchored MT1-MMP (i.e., MT1-MT6 · GPI) are consistently lower than those observed with other tethered constructs (presumably due to surface shedding; Sohail et al., 2008
TM) or the MT1/MMP-1CAT chimera (i.e., MT1/MMP-1CAT
TM), transfected COS cells lose all degradative or tissue-invasive activity (Figure 5C). Hence, significant pericellular collagenolytic as well as tissue-invasive activity are retained within the hemopexin-free extracellular domains of the membrane-tethered proteinase.
|
PEX mutant is devoid of almost all fibrin-invasive activity (Figure 6B). Interestingly, the requirement for an intact hemopexin domain to confer fibrin-invasive activity is not confined to the MT1-MMP hemopexin domain per se. Despite the fact that the MT3-MMP hemopexin domain cannot support fully the collagen-invasive activity of MT1-MMP (Figure 4), the MT1-MT3HPX chimera displays full fibrinolytic and proinvasive activities (Figure 6, A and B). Finally, as observed for collagenous substrates, fibrin-invasive activity is maintained when the transmembrane and cytosolic domains of MT1-MMP are replaced with a GPI anchor (Figure 6B). Hence, in contrast with the more relaxed structural requirements underlying collagenolytic activity, MT1-MMP–dependent fibrinolysis displays a strict reliance on both MT-MMP–derived catalytic and hemopexin domains. | DISCUSSION |
|---|
|
|
|---|
At first glance, the manner in which cellular behavior as complex as 3-D invasion can be incorporated into a relatively simple structural design wherein the appropriate proteolytic activity is passively tethered to the cell surface is not easily reconciled with existing paradigms in the literature (Itoh and Seiki, 2006
; Nyalendo et al., 2007
; D'Alessio et al., 2008
). Until recently, many of the specialized properties of MT1-MMP activity were attributed to the proteinase's ability to activate the MMP-2 or MMP-13 zymogens (Sato et al., 2005
; Itoh and Seiki, 2006
). MT1-MMP can, however, directly exert potent proteolytic effects against a variety of ECM substrates, including type I collagen and fibrin (Pei and Weiss, 1996
; d'Ortho et al., 1997
; Ohuchi et al., 1997
; Hiraoka et al., 1998
; Hotary et al., 2000
; Koshikawa et al., 2005
; Itoh and Seiki, 2006
). Consistent with earlier reports that neither MMP-2–/– nor MMP-13–/– fibroblasts, endothelial cells or vascular smooth muscle cells display defects in matrix degradation or invasion (Chun et al., 2004
; Sabeh et al., 2004
; Filippov et al., 2005
), the invasive potential of HT-1080 cells can be reconstituted in COS cells by "simply" expressing MT1-MMP in the absence of these accessory MMPs.
In an effort to better rationalize the ability of MT1-MMP to mediate its proinvasive effects in a stand-alone manner, our attention alternatively focused on the unusually broad substrate specificity of its catalytic domain (Tam et al., 2004b
; Itoh and Seiki, 2006
). Independent of potential ECM substrates, MT1-MMP has been reported to modify cell function by processing integrins, adhesion molecules, cell surface proteoglycans, or surface receptors (Sato et al., 2005
; Itoh and Seiki, 2006
; Abd El-Aziz et al., 2007
; Basile et al., 2007
; Freudenberg and Chen, 2007
). In keeping with these observations, we considered the possibility that by exchanging the MT1-MMP catalytic domain with that of the structurally distinct collagenase MMP-1, pericellular collagenolytic activity might be retained, whereas the higher order, functional activity associated with 3-D invasive behavior would be lost. Instead, the ability to confer collagenolytic as well as tissue-invasive activity was not necessarily restricted to the MT1-MMP catalytic domain. Conceivably, the substrate specificity of the inserted MMP-1 catalytic domain could have been redirected toward that of wild-type MT1-MMP by the MT1-MMP hemopexin domain itself. Indeed, the MT1-MMP hemopexin domain has previously been assigned critical roles in regulating collagenolytic activity by 1) supporting MT1-MMP dimerization at the cell surface, 2) mediating the local unwinding of the type I collagen triple-helix, and 3) acting as collagen-binding moiety that anchors the protease to its target substrate (Lehti et al., 2002
; Tam et al., 2004a
; Itoh et al., 2006
; Itoh and Seiki, 2006
; Lafleur et al., 2006
). As such, the ability of hemopexin-deleted MT1-MMP or the hemopexin-deleted MT1/MMP-1CAT chimera to confer COS cells with the ability to degrade type I collagen, invade collagen gels, or traverse interstitial tissues in the in vivo setting contradicts a series of recent studies. With regard to the ability of hemopexin-deleted MT1-MMP constructs to display collagenolytic activity, Itoh and colleagues reported that COS cells expressing the hemopexin deletion mutant are incapable of degrading a subjacent bed of type I collagen fibrils (Itoh et al., 2006
). Collagenolysis was, however, monitored in a qualitative manner via a colorimetric technique that lacks the sensitivity of our assay system, and invasive activity was not assessed. Because hemopexin-deleted MT1-MMP expresses
50% of the collagenolytic activity of the wt enzyme, we posit that this degree of activity was likely overlooked in the absence of quantifiable endpoints. Similarly, whereas MT1
PEX was reported to be incapable of supporting collagen-invasive activity (Wang et al., 2004
), the type I collagenolytic activity of the construct was not examined. Furthermore, invasion was monitored in Madin-Darby canine kidney (MDCK) cells, a well-differentiated epithelial cell line that already expresses a full complement of proinvasive MMPs (Kadono et al., 1998
; Hotary et al., 2000
). In our hands, MDCK cells engineered to overexpress wt MT1-MMP fail to express heightened invasive activity unless stimulated with motogens that transiently disrupt the cadherin-rich adherens junctions that normally serve as powerful repressors of motility in the 3-D setting (Kadono et al., 1998
; Hotary et al., 2000
).
The above-mentioned issues notwithstanding, the ability of MT1
PEX to mediate collagenolysis and invasion through collagen-rich barriers is puzzling because these results further demonstrate that neither the triple-helicase nor collagen-binding activities of the hemopexin domain play required roles in supporting MT1-MMP function in an intact cell system. These results are, however, consistent with recent studies demonstrating that MT1-MMP–mediated triple-helicase activity may reside within the catalytic domain itself and that the collagenolytic activity of secreted MMPs, including MMP-8 and MMP-2, are retained in the absence of their respective hemopexin domains (Gioia et al., 2002
; Minond et al., 2006
; Gioia et al., 2007
). The fact that the MT1-MMP hemopexin domain is dispensable for collagen remodeling contrasts with the observation that both fibrinolytic and fibrin-invasive activity proved to be hemopexin dependent, a finding similar to that recently reported for MMP-2–dependent fibrinogenolysis where the hemopexin domain participates directly in fibrin binding (Monaco et al., 2007
). It should be stressed, however, that our results do not support a conclusion that the hemopexin domain is functionless with regard to collagen turnover. Clearly, MT1
PEX is a less efficient collagenolysin and proinvasive factor than is the wild-type proteinase. Furthermore, the hemopexin domain may regulate MT1-MMP binding interactions with other accessory molecules that modulate cell functions other than those required for collagenolysis or invasion per se (e.g., collagen internalization) (Itoh and Seiki, 2006
; Lee et al., 2006
). Nevertheless, the ability of hemopexin-deleted MT1-MMP constructs to retain significant collagenolytic activity in tandem with an almost complete loss of fibrinolytic activity indicates that current paradigms regarding MT1-MMP function in the context of intact cell systems need be revisited and reconsidered.
Having established a required role for collagenolytic activity during invasion that cannot be recapitulated by secreted collagenases, we confirmed the fact that transmembrane-deleted, secreted forms of MT1-MMP are unable to confer tissue-invasive activity. These findings might seem to support reports documenting important roles for the MT1-MMP transmembrane domain and/or cytosolic tail in regulating MT1-MMP oligomerization, proteolytic activity, endocytosis, and recycling (Wu et al., 2005
; Itoh and Seiki, 2006
; D'Alessio et al., 2008
). We find, however, that tail-deleted MT1-MMP as well as the tail-deleted MT1/MMP-1CAT chimera is able to focus proteolytic activity at the membrane surface to drive pericellular collagenolysis and invasion. Although we considered the possibility that the MT1-MMP transmembrane domain itself might embed trafficking or membrane localization signals critical to proteolytic function, MT1-MMP mutants retain wild-type-like activity when the transmembrane domain is replaced with the GPI anchor of MT6-MMP. GPI-anchored MT1-MMP has recently been shown to support cell growth in 3-D collagen gels, but its ability to confer invasive activity was not examined (Nie et al., 2007
). Hence, despite earlier suggestions that higher order functions for the MT1-MMP C-terminus might be restricted to cells engaged in traversing ECM barriers (Uekita et al., 2001
; Itoh and Seiki, 2006
), our results demonstrate that tissue-invasive activity is retained when either the MT1-MMP transmembrane domain or cytosolic tail is deleted.
Despite the fact that MT1-MMP can effectively mediate subjacent proteolysis and proinvasive activity when shorn of its transmembrane and cytoplasmic domains, these findings should not be construed to suggest that these structures are devoid of functional activity. By controlling MT1-MMP recycling, the cytosolic tail can serve as a means to regenerate the active proteinase from inactive MT1-MMP–TIMP-2 complexes formed at the cell surface (Maquoi et al., 2000
; Zucker et al., 2004
). Indeed, tail-deleted MT1-MMP rendered cells hypersensitive to the inhibitory effects of TIMP-2 during collagen invasion. We should also stress that MT1-MMP–mediated effects on cell function need not be confined to motility or invasion. For example, the MT1-MMP cytosolic tail has been reported to control vascular endothelial growth factor expression via a src-dependent pathway and may induce other signaling pathways as well (Labrecque et al., 2004
; Sounni et al., 2004
; Nyalendo et al., 2007
; D'Alessio et al., 2008
). Furthermore, in preliminary studies, we have found that the MT1-MMP tail plays a critical role in regulating basolateral sorting and branching morphogenesis in polarized epithelial cells (unpublished observation). From these perspectives, a narrow focus on tissue-invasive properties alone may oversimplify the complex functions required of MT1-MMP during growth and development in vivo. Even so, our data demonstrate that a remarkable amount of functional information can be conveyed by a relatively simple proteinase construct and that predicted requirements for the MT1-MMP, catalytic, hemopexin, transmembrane, or cytoplasmic domains during invasion can be bypassed in vitro as well as in vivo. Of course, complex functions assigned to a "simple" protease in intact cell systems are, in part, illusory. By initiating ECM remodeling, cell function is likely modulated by a litany of associated events, including the release of bioactive matrix fragments, alterations in pericellular matrix rigidity, and the consequent effects on cell shape as well as gene expression (Chun et al., 2006
; Itoh and Seiki, 2006
; Freudenberg and Chen, 2007
; Cao et al., 2008
). Nevertheless, our studies demonstrate that by purposefully restricting the collagenolytic or fibrinolytic activity of MT1-MMP to the pericellular milieu, the cell can remodel multicomponent tissue barriers while maintaining the necessary adhesive interactions with the surrounding ECM to support propulsive 3-D movement.
| ACKNOWLEDGMENTS |
|---|
| Footnotes |
|---|
Address correspondence to: Stephen J. Weiss (sjweiss{at}umich.edu)
| REFERENCES |
|---|
|
|
|---|
Anilkumar, N., Uekita, T., Couchman, J. R., Nagase, H., Seiki, M., and Itoh, Y. (2005). Palmitoylation at Cys574 is essential for MT1-MMP to promote cell migration. FASEB J 19, 1326–1328.
Atkinson, S. J., Roghi, C., and Murphy, G. (2006). MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. Biochem. J 398, 15–22.[CrossRef][Medline]
Basile, J. R., Holmbeck, K., Bugge, T. H., and Gutkind, J. S. (2007). MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J. Biol. Chem 282, 6899–6905.
Brinckerhoff, C. E., and Matrisian, L. M. (2002). Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol 3, 207–214.[CrossRef][Medline]
Cao, J., Chiarelli, C., Richman, O., Zarrabi, K., Kozarekar, P., and Zucker, S. (2008). Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J. Biol. Chem 283, 6232–6240.
Cao, J., Kozarekar, P., Pavlaki, M., Chiarelli, C., Bahou, W. F., and Zucker, S. (2004). Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration. J. Biol. Chem 279, 14129–14139.
Chun, T. H., Hotary, K. B., Sabeh, F., Saltiel, A. R., Allen, E. D., and Weiss, S. J. (2006). A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell 125, 577–591.[CrossRef][Medline]
Chun, T. H., Sabeh, F., Ota, I., Murphy, H., McDonagh, K. T., Holmbeck, K., Birkedal-Hansen, H., Allen, E. D., and Weiss, S. J. (2004). MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol 167, 757–767.
D'Alessio, S. et al. (2008). Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J. Biol. Chem 283, 87–99.
d'Ortho, M. P., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilovic, J., Smith, B., Timpl, R., Zardi, L., and Murphy, G. (1997). Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur. J. Biochem 250, 751–757.[Medline]
English, W. R., Holtz, B., Vogt, G., Knauper, V., and Murphy, G. (2001). Characterization of the role of the "MT-loop": an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. J. Biol. Chem 276, 42018–42026.
Fabbri, M., Fumagalli, L., Bossi, G., Bianchi, E., Bender, J. R., and Pardi, R. (1999). A tyrosine-based sorting signal in the beta2 integrin cytoplasmic domain mediates its recycling to the plasma membrane and is required for ligand-supported migration. EMBO J 18, 4915–4925.[CrossRef][Medline]
Filippov, S. et al. (2005). MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J. Exp. Med 202, 663–671.
Freudenberg, J. A., and Chen, W. T. (2007). Induction of Smad1 by MT1-MMP contributes to tumor growth. Int. J. Cancer 121, 966–977.[CrossRef][Medline]
Gioia, M., Fasciglione, G. F., Marini, S., D'Alessio, S., De Sanctis, G., Diekmann, O., Pieper, M., Politi, V., Tschesche, H., and Coletta, M. (2002). Modulation of the catalytic activity of neutrophil collagenase MMP-8 on bovine collagen I. Role of the activation cleavage and of the hemopexin-like domain. J. Biol. Chem 277, 23123–23130.
Gioia, M., Monaco, S., Fasciglione, G. F., Coletti, A., Modesti, A., Marini, S., and Coletta, M. (2007). Characterization of the mechanisms by which gelatinase A, neutrophil collagenase, and membrane-type metalloproteinase MMP-14 recognize collagen I and enzymatically process the two alpha-chains. J. Mol. Biol 368, 1101–1113.[CrossRef][Medline]
Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R., and Weiss, S. J. (1998). Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95, 365–377.[CrossRef][Medline]
Hotary, K., Allen, E., Punturieri, A., Yana, I., and Weiss, S. J. (2000). Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol 149, 1309–1323.
Hotary, K., Li, X. Y., Allen, E., Stevens, S. L., and Weiss, S. J. (2006). A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 20, 2673–2686.
Hotary, K. B., Allen, E. D., Brooks, P. C., Datta, N. S., Long, M. W., and Weiss, S. J. (2003). Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114, 33–45.[CrossRef][Medline]
Hotary, K. B., Yana, I., Sabeh, F., Li, X. Y., Holmbeck, K., Birkedal-Hansen, H., Allen, E. D., Hiraoka, N., and Weiss, S. J. (2002). Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J. Exp. Med 195, 295–308.
Hurst, D. R., Schwartz, M. A., Ghaffari, M. A., Jin, Y., Tschesche, H., Fields, G. B., and Sang, Q. X. (2004). Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities. Biochem. J 377, 775–779.[CrossRef][Medline]
Itoh, Y., Ito, N., Nagase, H., Evans, R. D., Bird, S. A., and Seiki, M. (2006). Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol. Biol. Cell 17, 5390–5399.
Itoh, Y., and Seiki, M. (2006). MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol 206, 1–8.[CrossRef][Medline]
Jiang, A., and Pei, D. (2003). Distinct roles of catalytic and pexin-like domains in membrane-type matrix metalloproteinase (MMP)-mediated pro-MMP-2 activation and collagenolysis. J. Biol. Chem 278, 38765–38771.